Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan T Kielstein

Showing results (1-10 of 265) with videos related to

Pageof 27
Sort By:
Wiener Klinisches Magazin : Beilage Zur Wiener Klinischen Wochenschrift|June 26, 2023
[Hemoperfusion and plasmapheresis in the intensive care unit]Jan T Kielstein
The New England Journal of Medicine|November 8, 2013
Glucose levels and risk of dementiaJan T Kielstein
MMW Fortschritte Der Medizin|June 25, 2014
[The deadly sins of pharmacotherapy in chronic kidney disease]Jan T Kielstein
Critical Care Medicine|February 18, 2022
Is This the Beginning of the End of Cytokine Adsorption?Jan T Kielstein, Alexander Zarbock
Nature Clinical Practice. Nephrology|August 26, 2006
Technology Insight: treatment of renal failure in the intensive care unit with extended dialysisDanilo Fliser, Jan T Kielstein
Current Pharmaceutical Biotechnology|May 11, 2011
Dosing of antibiotics in critically ill patients undergoing renal replacement therapyJan T Kielstein, Olaf Burkhardt
The Annals of Thoracic Surgery|May 1, 2012
Symmetrical dimethylarginine as a biomarker for acute kidney injuryOktay Tutarel, Jan T Kielstein
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 24, 2017
Opponent's commentsCarsten Hafer, Jan T Kielstein
Current Opinion in Nephrology and Hypertension|October 23, 2008
Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney diseaseJan T Kielstein, Carmine Zoccali
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 23, 2005
Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?Jan T Kielstein, Carmine Zoccali
Pageof 27

Showing results (1-10 of 265) with videos related to

Sort By:
Pageof 27
Wiener Klinisches Magazin : Beilage Zur Wiener Klinischen Wochenschrift|June 26, 2023
[Hemoperfusion and plasmapheresis in the intensive care unit]Jan T Kielstein
The New England Journal of Medicine|November 8, 2013
Glucose levels and risk of dementiaJan T Kielstein
MMW Fortschritte Der Medizin|June 25, 2014
[The deadly sins of pharmacotherapy in chronic kidney disease]Jan T Kielstein
Critical Care Medicine|February 18, 2022
Is This the Beginning of the End of Cytokine Adsorption?Jan T Kielstein, Alexander Zarbock
Nature Clinical Practice. Nephrology|August 26, 2006
Technology Insight: treatment of renal failure in the intensive care unit with extended dialysisDanilo Fliser, Jan T Kielstein
Current Pharmaceutical Biotechnology|May 11, 2011
Dosing of antibiotics in critically ill patients undergoing renal replacement therapyJan T Kielstein, Olaf Burkhardt
The Annals of Thoracic Surgery|May 1, 2012
Symmetrical dimethylarginine as a biomarker for acute kidney injuryOktay Tutarel, Jan T Kielstein
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 24, 2017
Opponent's commentsCarsten Hafer, Jan T Kielstein
Current Opinion in Nephrology and Hypertension|October 23, 2008
Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney diseaseJan T Kielstein, Carmine Zoccali
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 23, 2005
Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?Jan T Kielstein, Carmine Zoccali
Pageof 27